Diamyd Medical
Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development.
Launch date
Employees
Market cap
AUD269m
Enterprise valuation
AUD239m (Public information from Sep 2024)
Share price
SEK14.58 DMYD-B.ST
Company register number 556242-3797
Stockholms kommun Stockholm County (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
| % growth | (74 %) | (26 %) | 79 % | 20 % | 449 % | - | - |
| EBITDA | 1.1m | (9.1m) | (11.6m) | (12.2m) | (14.5m) | (17.8m) | (21.7m) |
| % EBITDA margin | 3046 % | (32860 %) | (23246 %) | (20367 %) | (4400 %) | (5400 %) | (6567 %) |
| Profit | 1.1m | 6.6m | (11.4m) | (12.8m) | (14.6m) | (18.2m) | (22.1m) |
| % profit margin | 2847 % | 23734 % | (22802 %) | (21259 %) | (4433 %) | (5500 %) | (6700 %) |
| EV / revenue | 7821.3x | 8984.4x | 2207.1x | 1304.6x | 499.3x | 535.7x | 534.3x |
| EV / EBITDA | 256.7x | -27.3x | -9.5x | -6.4x | -11.3x | -9.9x | -8.1x |
| R&D budget | 1.5m | 6.3m | 8.3m | 7.7m | - | - | - |
| R&D % of revenue | 4050 % | 22475 % | 16645 % | 12804 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| N/A | SEK150m | Post IPO Equity | |
* | $5.0m | Grant | |
* | N/A | SEK57.0m | Post IPO Equity |
| Total Funding | AUD7.7m | ||
Related Content
Recent News about Diamyd Medical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.